Schizophrenia is a common disease with a complex aetiology, probably involving multiple and heterogeneous genetic factors. Here, by analysing the exome sequences of 2,536 schizophrenia cases and 2,543 controls, we demonstrate a polygenic burden primarily arising from rare (less than 1 in 10,000), disruptive mutations distributed across many genes. Particularly enriched gene sets include the voltage-gated calcium ion channel and the signalling complex formed by the activity-regulated cytoskeleton-associated scaffold protein (ARC) of the postsynaptic density, sets previously implicated by genome-wide association and copy-number variation studies. Similar to reports in autism, targets of the fragile X mental retardation protein (FMRP, product of FMR1) are enriched for case mutations. No individual gene-based test achieves significance after correction for multiple testing and we do not detect any alleles of moderately low frequency (approximately 0.5 to 1 per cent) and moderately large effect. Taken together, these data suggest that population-based exome sequencing can discover risk alleles and complements established gene-mapping paradigms in neuropsychiatric disease.
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Genetic studies of schizophrenia (MIM 181500) have demonstrated a substantial heritability 1,2 that reflects common and rare alleles at many loci. Genome-wide association studies (GWAS) continue to uncover common single nucleotide polymorphisms (SNPs) at novel loci 3 . Rare or de novo genic deletions and duplications (copy-number variants (CNVs)) have been firmly established, including risk variants at 22q11.2, 15q13.3 and 1q21.1 (refs 4, 5) . One notable outcome of these large-scale, genomewide investigations is the degree of polygenicity, consistent with thousands of genes and non-coding loci harbouring risk alleles 3, [6] [7] [8] [9] . Nonetheless, progress has been made in implicating biological systems and quantifying shared genetics among related psychiatric disorders (for example, refs 10, 11), such as identifying common variants in calcium ion channel genes affecting schizophrenia and bipolar disorder 12 and de novo CNVs affecting genes encoding members of the postsynaptic density (PSD) proteome 13 , in particular members of the neuronal ARC protein and N-methyl-D-aspartate receptor (NMDAR) postsynaptic signalling complexes.
Here we apply massively parallel short-read sequencing to assay a substantial portion of variation that previously was essentially invisible: rare coding point mutations (single nucleotide variants (SNVs)) and small insertions and deletions (indels). Although previous schizophrenia studies have applied sequencing, the results have been inconclusive, reflecting limited sample sizes or a focus on small numbers of candidate genes [14] [15] [16] [17] . Exome-sequencing studies of de novo mutations published to date have neither demonstrated an increased rate in schizophrenia, nor conclusively implicated individual genes 18, 19 , although some data suggest a link with particular classes of gene, such as those with higher brain expression in early fetal life 19 . De novo studies in intellectual disability 20, 21 and autism [22] [23] [24] [25] have, however, made considerable progress in identifying large-effect alleles and the underlying gene networks.
In this study, we sought to identify the alleles, genes or gene networks that harbour rare coding variants of moderate or large effect on risk for schizophrenia by exome sequencing 5,079 individuals, selected from a Swedish sample of more than 11,000 individuals. Previous analyses of the full sample (Supplementary Information section 1) have demonstrated an enriched burden of rare CNVs and a polygenic common variant component 3 . We generated high-coverage exome sequence to ensure sufficient sensitivity to detect and genotype alleles observed in only one heterozygous individual (singletons, implying an allele frequency of ,1 in 10,000, although the true population frequency will typically be rarer).
The high baseline rate of rare, neutral mutations makes it difficult to detect rare alleles that increase risk for common diseases 26 . Although power can be increased by jointly testing groups of variants in a gene 27 , association testing across all genes is likely to be under-powered at current sample sizes. Indeed, a recent application of population-based exome sequencing in autism did not identify genes 28 , despite moderately large sample size and the success of the de novo paradigm. Furthermore, many confirmed results from candidate-gene sequencing studies of nonpsychiatric disease still fall short of exome-wide significance 29 .
We therefore adopted a top-down strategy in which we studied a large set of genes with a higher likelihood of having a role in schizophrenia, on the basis of existing genetic evidence (Supplementary Information section 7). We focused on ,2,500 genes implicated by unbiased, large-scale genome-wide screens, including GWAS, CNV and de novo SNV studies, testing for enrichment of rare alleles in cases. To prioritize individual genes, we characterized emerging signals with respect to the genes and frequency and type of mutations. We coordinated analysis with an independent trio exome-sequencing study (Fromer et al. 30 , this issue) and note key points of convergence below.
After alignment and variant calling of all samples jointly, we removed 11 subjects with low-quality data along with likely spurious sites and genotypes (Supplementary Information sections 2 and 3). Per individual, 93% of targeted bases were covered at $10-fold (81% at $30-fold). The final data set comprised 2,536 cases and 2,543 controls (Extended Data Table 1a and Extended Data Fig. 1a ). Cases and controls had similar technical sequencing metrics, including total coverage, proportion of deeply covered targets, and overall proportion of non-reference alleles (Extended Data Table 1b) . We observed 635,944 coding and splice-site passing variants of which 56% were singletons. Using Sanger sequencing and Exome Chip data on these samples, we determined high specificity and sensitivity for singletons (Supplementary Information section 3) .
We annotated variants with respect to RefSeq and combined five in silico algorithms to predict missense deleteriousness (Extended Data  Table 1c and Supplementary Information section 4). As expected, allelic types more likely to affect protein function showed greater constraint: 69% of nonsense variants were singletons, compared to 58% of missense and 51% of silent variants. Primary analyses tested (1) disruptive variants (nonsense, essential splice site and frameshifts, n 5 15,972 alleles with minor allele frequency (MAF) , 0.1%); (2) disruptive plus missense variants predicted to be damaging by all five algorithms (n 5 50,369); and (3) disruptive plus missense variants predicted to be damaging by at least one algorithm (n 5 233,575). These groups are labelled disruptive, NS strict and NS broad , in which NS indicates nonsynonymous. We also stratified most analyses by allele frequency: (1) singletons; (2) up to 0.1% (ten or fewer minor alleles); and (3) up to 0.5% (50 or fewer minor alleles). In the main gene set analyses, we empirically corrected for multiple testing over the nine combinations of these factors (Supplementary Information section 7).
The most significant SNV or indel association (P 5 5 3 10 8 ) was for a common missense allele in CCHCR1, in the major histocompatibility complex (MHC), a known risk locus; this top SNP was in linkage disequilibrium with many other schizophrenia-associated SNPs in the MHC. All P , 10 25 variants were for either common alleles or a few instances of likely aberrant variants that had escaped earlier filtering (Supplementary Information section 5). We performed two series of gene-based tests: a one-sided burden test of an increased rare allele rate in cases, and the SNP-set (sequence) kernel association test (SKAT 27 ), which allows for risk and protective effects. For both tests, the distribution of gene-based statistics broadly followed a global null (Extended Data Fig. 1b) .
Considering only disruptive variants, the genic test yielding the lowest nominal P value was for KYNU (kynureninase), showing ten variants in cases and zero in controls (Extended Data Table 2 and Supplementary  Table 1) ; one novel nonsense mutation at chr2:143713804 (g.468T.A; p.Y156*) was observed in seven cases and not present in either the Exome Variant Server (http://evs.gs.washington.edu/EVS/) or 1000 Genomes Project (http://www.1000genomes.org/). Although previous studies have suggested links between the kynurenine pathway and schizophrenia 31 , our P value of 1.7 3 10 23 does not withstand correction for multiple testing, even if considering only the 246 genes with $10 rare disruptive mutations capable of achieving a nominally significant result.
A polygenic burden of rare coding variants
We evaluated a polygenic burden of rare coding variants in cases, first selecting 2,546 genes (,10% of the exome) on the basis of previous genetic studies that we proposed to be enriched for schizophreniaassociated mutations (Supplementary Information section 6). Sources included genome-wide CNV studies 5, 13 , GWAS 3, 12, 32 and exome sequencing of de novo mutations 18, 19, 30 . In our sample, these genes had a significantly higher rate of rare (MAF , 0.1%), disruptive mutations in cases compared to controls (P 5 10 24 for 1,547 versus 1,383 mutations). The enrichment was unlikely to represent technical or ancestry-related artefact because the P values controlled for potential differences in exomewide burden in cases and controls, and because we observed no differences exome wide (P 5 0.24). Furthermore, enrichment P values were empirically derived by permuting phenotypes within subgroups of cases and controls, matched on exome-wide identity-by-state, experimental batch and sex; the above result withstood correction for multiple testing (Table 1) . We observed similar results for rarer (singletons, P 5 8 3 10
24
) and more frequent (MAF , 0.5%, P 5 2 3 10
) alleles. We also observed case enrichment for the strictly defined set of damaging mutations (NS strict , P 5 1.5 3 10
23
) but not the broader set (NS broad , P 5 0.13). 
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This enrichment suggests a polygenic burden of rare variants. Although not so marked as to be detectable at the exome-wide level given the sample size, it is relatively concentrated in genes that were found to be associated with schizophrenia by other methods. The mean allelic effect was not large: in the primary comparison, the odds ratio was 1.12 (1.04-1.20, 95% confidence interval) for each MAF , 0.1% disruptive mutation; 46% of cases carried one or more allele in this primary set (0.62 per case) compared to 41% of controls (0.55 per control). At two extremes, the modest mean effect could represent either that a subset of mutations are fully penetrant or that every allele is associated but increases risk by only 12%, similar to common alleles from GWAS. To extract subsets of potentially stronger-effect alleles, we individually tested the constituent gene sources (Table 1 and Extended Data Fig. 1c) , focusing on disruptive variants as they showed the strongest omnibus enrichment. For disruptive mutations, eight out of 12 sets were nominally significant (P , 0.05), indicating that the initial observation was not driven by a single category.
ARC, PSD-95 and calcium ion channel genes
Three of the smaller significantly enriched sets (the ARC and PSD-95 (encoded by DLG4) complexes and calcium ion channel genes) had odds ratios .5. We observed enrichment (P 5 1.6 3 10 23 ) of disruptive mutations among the 28 ARC complex genes: nine mutations in nine genes (all singletons) in cases and zero in controls, yielding an odds ratio of 19.2 (2.4-2,471, 95% confidence interval; Extended Data Table 2 ). Along with the NMDAR gene set (also significantly enriched), ARC genes largely accounted for the overall PSD enrichment (P 5 4 3 10 28 ) in ref. 13 , in which four ARC genes had one or more de novo CNVs. Of note, in an independent exome-sequencing study in trios, Fromer et al. 30 found that the ARC gene set was enriched (P 5 5 3 10
24
) for nonsynonymous de novo SNVs and indels, with four genes harbouring six mutations (Extended Data Table 7 ). The other PSD gene set with strong enrichment (P 5 9 3 10 24 ; odds ratio 5 5.1, 1.8-19.2, 95% confidence interval) was the PSD-95 complex, which contains 65 genes and overlaps with ARC. PSD genes are very highly conserved and have critical roles in excitatory neural signalling components, as well as dendrite and spine plasticity. Further categorization of neuronal genes on the basis of subcellular localization 13 (Extended Data Table 3a ) or associated mouse and human phenotypes 33 did not yield further enrichment.
The other subset yielding a large odds ratio of 8.4 (2.03-77, 95% confidence interval) was the 26 voltage-gated calcium ion channel genes (12 cases, one control; disruptive singletons, P 5 2 3 10 23 , although the effect is attenuated when including recurrent alleles: 15/8 cases/ controls, P 5 0.021, see Extended Data Table 2 ). The singleton enrichment was predominantly driven by the pore-forming a 1 and auxiliary a 2 d subunits; of the a 1 subunits, the Ca V 1/L-type genes carried the most case mutations, including two in CACNA1C, a gene implicated by GWAS of bipolar disorder and schizophrenia 3, 10 . Calcium signalling is involved in many cell functions including the regulation of gene expression 34 and is critical for modulating synaptic plasticity 35 . In a secondary analysis of proteins found in the nano-environment of the calcium channel 36 , we observed independent enrichment for other ion channel transporters (Supplementary Table 1 
, from 47 genes in our study); these genes included UFL1 (5/0 disruptive mutations, P 5 0.03; 7/0 NS strict , P 5 0.008), SYNGAP1 (4/0 NS strict , P 5 0.04) and SZT2 (18/9 NS strict , P 5 0.049). SYNGAP1 (synaptic Ras GTPase activating protein 1) is a component of the NMDAR PSD complex 37 and mutations in this gene are known to cause intellectual disability and autism 38 . Genes under previously associated CNV regions did not show significant enrichment of rare disruptive mutations, although there was an enrichment of NS strict mutations (P 5 0.0044; Extended Data Table 4 ). Of the 11 CNV regions, only the 3q29 locus, which contains multiple genes including DLG1 (ref. 4) , was significant (P 5 0.0006) and withstood correction for multiple testing.
Autism/intellectual disability genes and FMRP targets
We next tested, as a single set, the 2,507 genes representing autism and intellectual disability candidates (Supplementary Information section 6), which yielded only nominal significance (P , 0.05) for disruptive and NS strict variants and no test survived correction for multiple testing ( Table 2 ). Considering the 12 constituent sets, genes from autism de novo Information section 6 ). In addition, these genes were enriched in GWAS of this sample (P , 10 23 , Supplementary Information section 9). Whereas the Darnell list is derived from mouse brain, a second recently reported FMRP target list 42 was generated from cultured human embryonic kidney cells, using a different experimental approach (Supplementary Information section 6). This list has relatively little overlap with Darnell targets and, in contrast to the Darnell list, does not show any enrichment for rare case mutations, for GWAS loci, or comparable overlap with PSD genes (Extended Data Table 3b ).
Our results are perhaps surprising: unlike Fromer et al. 30 , we did not observe direct evidence for overlap at the individual gene level with autism and intellectual disability, despite CNV studies showing pleiotropic effects of individual loci. Nonetheless, at the broader level of gene sets, all three disorders showed enrichment for FMRP targets; autism and intellectual disability de novo mutations also showed strong enrichment in several PSD complexes enriched in our study, including NMDAR, PSD-95 and (for intellectual disability) ARC. At the least, our results suggest that any overlap is far from complete, although more refined analyses in larger samples will be needed before a clearer picture can emerge of which genes and pathways are shared and which are specific to one disease.
Characterizing enrichment by variant type
To further characterize the observed enrichment with respect to mutational function and frequency, we created a single 'composite' set of 1,796 genes comprising all members of the most prominently enriched sets (Supplementary Table 2 ). Rare disruptive mutations in this set were present in 990 cases and 877 controls (for singletons, 645-530). Cases carrying rare disruptive mutations did not appear to be phenotypically or clinically unusual in terms of sex, ancestry, history of drug abuse, general medical conditions plausibly aetiologically related to psychosis, or epilepsy, although they did have a higher rate of admissions noting comorbid intellectual disability compared to other cases (P 5 0.009; Extended Data Table 2b ). Figure 1 shows composite set enrichment across a range of conditions. As this set merges other sets showing enrichment, it necessarily shows enrichment; it was not, however, due to confounding effects of ancestry, sex or experimental wave (Supplementary Information section 8). It was primarily driven by singleton nonsense mutations across a large number of genes, as it was removed or greatly attenuated when either singleton or nonsense mutations were excluded. Considered alone, neither splice-site, frameshift, missense, silent or noncoding mutations showed enrichment at P , 0.01. Different ways of defining damaging missense mutations did not substantively affect results. Considering only nonsynonymous coding variants present on Exome Chip, we did not observe enrichment. Rather, enrichment mainly reflected novel variants (Extended Data Table 5b ), which is expected as most rare variants in our study are novel. We also took an alternative approach, whereby instead of filtering variants on frequency, we excluded genes with any control disruptive variants before calculating the burden of case alleles; the composite set was still highly enriched ('case-unique' in Table 5b and Supplementary Information section 7). Finally, the enrichment could not be attributed to only a small number of variants or genes (Extended Data Fig. 2a ).
These findings do not preclude potentially important effects from other classes of rare variation in specific genes or other gene sets, although exploratory analyses of generic gene sets (for example, based on Gene Ontology terms) did not unambiguously identify novel signals after correction for multiple testing (Supplementary Information section 7). Statistical significance (x axis) for the composite gene set stratified by type and frequency of mutation and other variables. Numbers to the right of each bar represent the number of genes with at least one mutation in that category for the composite set. (S) represents strictly defined damaging missenses; (B) represents the broadly defined group. Nonsyn (all) represents all nonsynonymous mutations. Numbers to the left of the bars (1, 10, 50) represent the minor allele count threshold (i.e. 1 indicates a singleton-only analysis); here the ranges 2-10 and 2-50 represent analyses that excluded singletons; N/A indicates that no allele-wise threshold was used. The source of deleteriousness prediction algorithms (LRT, MutationTaster, PPH and SIFT) is described in the Supplementary Information. For the exome array contrasts, Exome Chip sites were tested using the exome sequence calls.
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We found preferential enrichment in genes with high brain expression, but not for genes with a prenatally biased developmental trajectory (Extended Data Fig. 3 ). In fact, greater enrichment came from postnatally biased genes. Finally, although greatly attenuated compared to disruptive mutations, other categories displayed nominal (0.01 , P , 0.05) enrichment in Fig. 1 and strictly defined damaging missense mutations alone showed enrichment for ARC and NMDAR gene sets (32/15 for ARC, P 5 0.007; Extended Data Tables 5a and 7) . Although rare coding alleles other than ultra-rare nonsense mutations will undoubtedly contribute to risk, it will probably prove harder still to elucidate such effects.
Rare variants, CNVs and common GWAS variants
We quantified the relative impact of common SNPs (indexed by a genome-wide polygene score from independent GWAS samples 32 ), rare CNVs (the burden of genic deletions) and disruptive mutations in the composite set. Considering the same 5,079 individuals, all three classes of variation were uncorrelated and significantly, independently and additively enriched in cases compared to controls. From logistic regression, the relative effect sizes (reduction in model R 2 ) were 5.7%, 0.2% and 0.4% for GWAS, rare CNV and rare coding variants, respectively (Supplementary Information section 8). Although not a complete assessment, it indicates that for the current sets of identifiably enriched alleles, common GWAS variants account for an order-of-magnitude more heritability than this set of rare variants does. However, these estimates will be diluted to varying degrees, owing to associated variants being included. As a consequence of this, and also the fact that true risk variants outside of composite set genes were not considered here, this estimate represents a conservative lower bound on the contribution of rare coding variation.
Discussion
We have demonstrated a polygenic burden that increases risk for schizophrenia, primarily comprising many ultra-rare nonsense mutations distributed across many genes. Implicating individual genes remains challenging, as genes that contributed to the highest-ranked sets typically had unremarkable P values, often around 0.5 with the gene containing only one or two rare mutations. Nonetheless, we were able to detect several small and highly enriched sets, notably of genes related to calcium channels and the postsynaptic ARC complex. Across these ,50 genes, ,1% of cases carried a rare disruptive mutation likely to have a considerable impact on risk. However, reported effect sizes will have a tendency to over-estimate true population values (Supplementary Information section 5).
We add to previous work that has implicated disruption of synaptic processes in schizophrenia 13 . The PSD is comprised of supramolecular multiprotein complexes that detect and discriminate patterns of neuronal activity and regulate plasticity processes responsible for learning 43 . Members of the membrane-associated guanylate kinase (MAGUK) family of scaffold proteins, such as PSD-95, have a key role in assembling ,2 MDa complexes comprising calcium channels, including the glutamate-gated NMDAR, voltage-gated calcium channels and ARC 36, 44 . The genetic disruption of MAGUKs and their associated components result in specific cognitive impairments in mice and humans 45 . One possibility is that the genetic risk identified here reflects altered tuning in calcium-dependent signalling cascades, triggered by NMDAR 46 and L-type calcium channels 47 , mediated by postsynaptic MAGUK signalling complexes driving ARC synthesis.
Although we cannot yet use rare mutations to partition patients into more homogeneous clinical subgroups, this will remain a central goal for future sequencing studies. The few population-based commondisease exome-sequencing studies published to date, in psychiatric (for example, ref. 28) and non-psychiatric (for example, ref. 48) diseases, have not been successful in finding individual genes showing significant enrichment. Our study yields similar findings for individual genes, but yields positive results when considering gene sets. These current findings are likely to foreshadow the definitive identification of individual genes in larger cohorts, following the trajectory of GWAS and other genetic studies of complex disease.
METHODS SUMMARY
Sample ascertainment. Cases with schizophrenia were identified through the Swedish Hospital Discharge Register 3 . Case inclusion criteria: $2 hospitalizations with a discharge diagnosis of schizophrenia, both parents born in Scandinavia, age $18 years. Case exclusion criteria: hospital register diagnosis of any disorder mitigating a confident diagnosis of schizophrenia. Controls were randomly selected from Swedish population registers. Control inclusion criteria: never hospitalized for schizophrenia or bipolar disorder, both parents born in Scandinavia, age $18 years. All subjects provided informed consent; institutional human subject committees approved the research. Sequencing. The samples (2, . Analyses controlled for ancestry and quality control metrics. Gene sets were evaluated on the empirical distribution of the sum of individual gene burden statistics, and incorporated an empirical correction for multiple testing. Odds ratios with 95% confidence intervals used penalized maximum likelihood (Firth's method) for low cell counts. See Supplementary Information for further details. Summary results are posted at http://research.mssm. edu/statgen/sweden/.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
15 ; singletons, P 5 8 3 10 24 ; significant after correction for multiple testing) whereas the autism/intellectual disability set shows only a modest trend (P 5 0.04 for MAF , 0.1% and P 5 0.03 for singletons) and is not significant after correction. x axis represents -log 10 (P); OR, odds ratio. Number of genes is for total in the set (whether or not they had a rare variant). Genes in the composite set (ordered by case burden) Empirical −log10(P) for best K genes in set The black line represents results for the real data (disruptive MAF , 0.1% composite set analysis). The orange line represents the dummy condition, in which we artificially constructed a set in which the number of genes, statistical enrichment, odds ratio and case/control counts were similar to the real composite set. However, this set included the 25 top-ranked genes from individual gene-based tests (disruptive MAF , 0.1% variants), with the remainder selected at random. The profile of the best test line is markedly different between the real and dummy gene sets (note: truncated at P 5 0.0001 reflecting the number of permutations performed). Whereas the dummy P value climbs quickly and then drops to the final aggregate result, the true composite set line continues to climb after 200 genes, indicating that many genes with a single disruptive mutation contribute to the observed set enrichment (rather than a relatively small proportion of the 1,796 genes accounting for the majority of the signal, as in the dummy set). b, Phenotypic characteristics of cases carrying mutations. Relationship between clinical and demographic measures in schizophrenia cases in relation to carrying one or more composite set disruptive risk alleles (MAF , 0.1%). Hospital Discharge Registry (HDR) data (ICD9 codes) were available on 979 of the 990 case carriers. All P values (uncorrected) are two-sided from a case-only joint logistic regression of carrier status (one or more risk alleles) on all admission and demographic variables including year of first and last admissions. The four pairs of columns represent analyses in which we varied the way in which the HDR admission data were represented (for drug abuse, general medication condition, epilepsy and intellectual disability). # admissions, independent variables are the untransformed number of admissions; .X admissions, independent variable is binary 0/1 variable representing whether individuals had more than X admissions. Of all clinical/demographic measures considered, we observed a nominally significant increased likelihood that cases carrying a disruptive allele in the composite set have increased rates of secondary diagnoses of intellectual disability compared to other cases (based on HDR ICD9 codes). ARTICLE RESEARCH Extended Data Figure 3 | Stratified enrichment analysis P values by developmental trajectory of expression in brain (BrainSpan and Human Brain Transcriptome (HBT) data sets). a, Uncorrected P values for a set of exploratory analyses in which we stratified genes in the enrichment analyses by their developmental profile of brain expression. We used four schemes to classify genes as 'brain expressed' and/or 'biased' with respect to prenatal or postnatal expression (see Supplementary Information section 6 for details). We merged data on the hippocampus and dorsolateral prefrontal cortex for the BrainSpan classifications; to mirror the classification of Xu et al. 19 we kept separate these two groupings for the HBT data set. Results presented for MAF , 0.1% disruptive variants; similar results were obtained for singletons with the exception that the 'K4' prenatal enrichment signals were no longer significant. In general, the most consistent enrichment across variant classes, classification schemes and brain regions emerges for postnatally biased genes with high brain expression. b, Analysis of exome variants by developmental expression trajectory in human brain. Genes are grouped by cluster analysis of human postmortem brain expression into eight developmental trajectories, using RNA-sequencing data from the BrainSpan project. The top row gives the number of genes per cluster and the cluster centres in log 2 -scaled RPKM (reads per kilobase per million) values; solid and dotted solid lines indicate dorsolateral prefrontal cortex (DLPFC) and hippocampus (HPC), respectively. The bottom two rows show enrichment in the current study, relative to the exome-wide average, for singleton disruptive mutations in cases compared to controls, either subsetting all genes by expression profile (first row), or considering only genes in the composite set (second row). In both cases, we only observed nominally (P , 0.01) significant enrichment for genes that are postnatally biased. By contrast, a list of genes with loss-of-function (LoF) de novo mutations (compiled and reported in Fromer et al.
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) shows strong enrichment for prenatal bias (see Fromer et al. 30 for details on how de novo enrichment was calculated). Alternative approaches to classifying genes as prenatally or postnatally biased led to similar conclusions (Supplementary Information section 6 ). 
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Extended Data Table 2 | Genes prioritized as more likely to harbour large-effect alleles Class Gene Singletons MAF < 0.1% Notes Voltage-gated calcium ion channel genes For all nine (three annotation levels by three frequency levels), P values for enrichment of all gene sets described and tested in Kirov et al. 13 . In addition to the PSD genes (top five rows), enrichment statistics for presynaptic genes, and neuronal genes clustered on the basis of subcellular location are given. Although the P values presented are uncorrected, we performed this analysis correcting for all 9 3 17 5 153 tests (by considering the distribution of the minimum empirical P value across tests and sets, as described in the Supplementary Information a, Gene set analyses for damaging missense mutations only. For the primary gene set and the 12 constituent subsets, a comparison of disruptive versus (strictly defined) damaging missenses, that is, an independent set of variants. The omnibus result for the primary test is modest (P 5 0.04) and did not withstand correction for multiple testing: as illustrated in Fig. 1 and the main text, the bulk of the enrichment signal we observe comes from (singleton) disruptive mutations. Nonetheless, specific gene sets such as ARC and the NMDAR network are highly and independently enriched for missense variants. N represents the number of genes with at least one mutation of this class observed in the sample. A/U represent case/control counts of non-reference genotypes. OR represents the odds ratio (not corrected for exome-wide rates) estimated by Firth's method for sets with small cell counts. All tests are empirical and one-sided (higher values expected in cases) as described in the main text and Methods. b, Enrichment analyses of novel and case-unique disruptive mutations. For primary and secondary gene sets (and constituent subsets) as well as the composite set: results of alternative burden analyses. First, focusing only on genes without any control disruptive variants; no further frequency filter is imposed. Here 'N genes(A/U)' indicates the number of genes with at least one disruptive variant, followed by the number of genes with case-only disruptive mutations and (for comparison) the number with control-only disruptive mutations. The 'A(U)' column gives the number of case variants in the case-only genes: the test statistic is based on the empirical distribution of this count. The U in this field represents the similar quantity for controls (not explicitly used in the statistic). The second set of analyses represent standard burden/enrichment tests (that is, as Tables 1 and 2 ) but stratified for novel versus known disruptive variants, according to dbSNP and the Exome Sequencing Project/Exome Variant Server (ESP/EVS) database. Novel variants show greater enrichment, although most rare variants observed in our study (both in cases and in controls) are novel, so tests of novel variants will have greater power.
Macmillan Publishers Limited. All rights reserved ©2014
Extended Data 18 . The P values in bold are significant at P corrected , 0.05, correcting for all 3 3 3 3 6 5 54 tests reported. b, Genes nominally significant (no correction) that had an observed de novo in one of the schizophrenia studies.
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